Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics.
Brainard
Diana M
DM
Merck & Co., Inc., Whitehouse Station, NJ, USA. diana_brainard@merck.com
Friedman
Evan J
EJ
Jin
Bo
B
Breidinger
Sheila A
SA
Tillan
Maria D
MD
Wenning
Larissa A
LA
Stone
Julie A
JA
Chodakewitz
Jeffrey A
JA
Wagner
John A
JA
Iwamoto
Marian
M
D000293:Adolescent; D000328:Adult; D018592:Cross-Over Studies; D004041:Dietary Fats / Q000008:administration & dosage*; D005260:Female; D018565:Food-Drug Interactions; D015658:HIV Infections / Q000188:drug therapy; D019428:HIV Integrase Inhibitors / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D000068898:Raltegravir Potassium; D055815:Young Adult
D004041:Dietary Fats; D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium